论文部分内容阅读
目的:探讨前B细胞白血病同源盒基因3（PBX3）和第10号染色体缺失的磷酸酶和张力蛋白同源等位基因（PTEN）在宫颈癌中的表达及与临床病理特征和预后的关系。方法:收集2014年6月至2018年12月南京市仙林鼓楼医院收治的85例宫颈癌患者的宫颈癌组织和癌旁组织，采用免疫组织化学法检测PBX3和PTEN表达水平。单因素分析和多因素Logistic回归模型分析PBX3和PTEN表达水平与临床病理特征的关系，Kaplan-Meier生存曲线分析PBX3和PTEN表达水平与预后的关系。结果:宫颈癌组织PBX3蛋白阳性表达率38.82%（33/85），高于癌旁组织的25.53%（20/85），PTEN蛋白阳性表达率36.47%（31/85），低于癌旁组织的98.82%（84/85），差异均有统计学意义（n χn 2=4.633，n P=0.031；n χn 2=75.500，n P<0.001）。单因素分析显示，宫颈癌组织PBX3和PTEN表达与临床分期、肿瘤分化程度、淋巴结转移、血管侵犯和肿瘤浸润程度有关（n P<0.05）。多因素Logistic回归模型显示，临床分期、肿瘤分化程度和淋巴结转移是宫颈癌组织PBX3或PTEN阳性表达的独立影响因素（n P<0.05）。PBX3阳性表达患者45.45%（15/33）死亡，中位生存时间31个月；阴性表达患者25.00%（13/52）死亡，中位生存时间38个月，Log-rank检验显示宫颈癌组织PBX3阳性表达患者与阴性表达患者生存情况比较差异有统计学意义（n P=0.025）。PTEN阳性表达患者22.58%（7/31）死亡，中位生存时间39个月；阴性表达患者38.89%（21/54）死亡，中位生存时间33个月，Log-rank检验显示宫颈癌组织PTEN阳性表达患者与阴性表达患者生存情况比较差异有统计学意义（n P=0.035）。n 结论:宫颈癌中PBX3表达上调，PTEN表达下调。PBX3和PTEN表达水平与临床分期、肿瘤分化程度和淋巴结转移均有关。宫颈癌组织PBX3阳性表达患者的预后差于阴性表达患者，PTEN阳性表达患者的预后好于阴性表达患者。“,”Objective:To investigate the expression of pre-B-cell leukemia homeobox 3 (PBX3) and the phosphatase and tensin homology deleted on chromosome 10 (PTEN) in cervical cancer and its relationship with the clinicopathologic characteristics and prognosis.Methods:Cervical cancer tissues and adjacent tissues of 85 patients with cervical cancer admitted to Xianlin Gulou Hospital from June 2014 to December 2018 were collected and the expression levels of PBX3 and PTEN were detected by immunohistochemistry. The univariate analysis and Logistic regression model were used to analyze the relationship between the expression levels of PBX3, PTEN and clinicopathologic features. Kaplan-Meier survival curve was used to analyze the relationship between the expression levels of PBX3, PTEN and prognosis.Results:The positive expression rate of PBX3 protein in cervical cancer tissues was higher than that in adjacent tissues: 38.82%(33/85) vs. 25.53%(20/85); the positive expression rate of PTEN protein was lower than that in adjacent tissues: 36.47%(31/85) vs. 98.82%(84/85), and there were significant differences (n P<0.05). The univariate analysis showed that the expression levels of PBX3 and PTEN were associated with clinical stages, degree of tumor differentiation, lymph node metastasis, vascular invasion, and degree of tumor invasion (n P<0.05). The multiple Logistic regression model showed that the clinical stages, tumor differentiation and lymph node metastasis were independent influencing factors for the positive expression of PBX3 or PTEN in cervical cancer tissues (n P<0.05). While 45.45%(15/33) of patients with positive PBX3 expression died, with a median survival of 31 months, and 25.00% (13/52)of patients with negative expression died, with a median survival of 38 months. Kaplan-rank test showed that the survival time in the patients with positive PBX3 expression and in the patients with negative expression had significant difference (n P=0.025). While 22.58%(7/31) of patients with positive PTEN expression died, with a median survival of 39 months, and 38.89%(21/54) of the patients with negative expression died, with a median survival time of 33 months. Kaplan-rank test showed that the survival time in the patients with positive PTEN expression and in the patients with negative expression had significant difference (n P=0.035).n Conclusions:The expression of PBX3 is up-regulated and PTEN is down-regulated in cervical cancer. The expression levels of PBX3 and PTEN are related to clinical stage, tumor differentiation and lymph node metastasis. The prognosis of the patients with positive PBX3 expression is worse than that of the patients with negative expression, and the prognosis of the patients with positive PTEN expression is better than that of the patients with negative expression.